rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer HTA
No takes yet. Share an insight, caveat, or question.
Jones et al. (2002) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: